|Send to printer »|
Columns : Jun 1, 2014 ( )
ISCO’s Parthenogenetic Core
Therapeutic Stem Cells from Unfertilized Eggs Sidestep Ethical Issues, Avoid Immune Rejection!--h2>
Committed to regenerative medicine but fundamentally opposed to the use of embryonic stem cells, the founders of International Stem Cell Corporation (ISCO) created a new class of pluripotent human stem cells. Now, eight years later, this work has resulted in UniStemCell™, the largest privately owned pluripotent stem cell bank.
Projects Are Preclinical
ISCO’s lead therapeutic candidate targets Parkinson’s disease. Dr. Semechkin says he expects to complete IND-enabling studies this year. The company had a pre-IND meeting with the FDA in February, and currently is working to complete the necessary tumorigenicity, toxicology, and tolerability studies.
ISCO, which is publicly traded on the OCTQB exchange, has a multifaceted business model. It includes the UniStemCell bank, development and partnering options for therapeutic cellular products, and two commercial subsidiaries selling biomedical research and dermatological products. Several initiatives are already providing revenue.
International Stem Cell Corporation (ISCO)
Location: 5950 Priestly Drive, Carlsbad, CA 92008
© 2016 Genetic Engineering & Biotechnology News, All Rights Reserved